Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
10/09/2024 | 19:09 | GlobeNewswire Inc. | CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes | NASDAQ:ALT | Altimmune Inc |
10/09/2024 | 13:45 | GlobeNewswire Inc. | Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes | NASDAQ:ALT | Altimmune Inc |
03/09/2024 | 13:30 | GlobeNewswire Inc. | Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes | NASDAQ:ALT | Altimmune Inc |
21/08/2024 | 00:05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
15/08/2024 | 22:14 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:ALT | Altimmune Inc |
15/08/2024 | 22:08 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:ALT | Altimmune Inc |
15/08/2024 | 22:03 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ALT | Altimmune Inc |
08/08/2024 | 22:07 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ALT | Altimmune Inc |
08/08/2024 | 13:00 | GlobeNewswire Inc. | Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update | NASDAQ:ALT | Altimmune Inc |
07/08/2024 | 13:00 | GlobeNewswire Inc. | CytoSorbents to Report Second Quarter 2024 Operating and Financial Results | NASDAQ:ALT | Altimmune Inc |
01/08/2024 | 13:30 | GlobeNewswire Inc. | Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 | NASDAQ:ALT | Altimmune Inc |
25/07/2024 | 13:30 | GlobeNewswire Inc. | Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology | NASDAQ:ALT | Altimmune Inc |
03/07/2024 | 11:45 | PR Newswire (US) | Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm | NASDAQ:ALT | Altimmune Inc |
02/07/2024 | 13:30 | GlobeNewswire Inc. | Altimmune to Participate at Leerink Partners Therapeutics Forum | NASDAQ:ALT | Altimmune Inc |
26/06/2024 | 13:30 | GlobeNewswire Inc. | Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt | NASDAQ:ALT | Altimmune Inc |
25/06/2024 | 11:45 | PR Newswire (US) | Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT | NASDAQ:ALT | Altimmune Inc |
23/06/2024 | 19:45 | GlobeNewswire Inc. | Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions | NASDAQ:ALT | Altimmune Inc |
22/06/2024 | 22:45 | GlobeNewswire Inc. | Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions | NASDAQ:ALT | Altimmune Inc |
20/06/2024 | 13:30 | GlobeNewswire Inc. | Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways | NASDAQ:ALT | Altimmune Inc |
20/06/2024 | 11:45 | PR Newswire (US) | Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT | NASDAQ:ALT | Altimmune Inc |
18/06/2024 | 13:30 | GlobeNewswire Inc. | Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions | NASDAQ:ALT | Altimmune Inc |
17/06/2024 | 11:45 | PR Newswire (US) | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT | NASDAQ:ALT | Altimmune Inc |
05/06/2024 | 13:00 | GlobeNewswire Inc. | Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) | NASDAQ:ALT | Altimmune Inc |
05/06/2024 | 11:45 | PR Newswire (US) | Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALT | NASDAQ:ALT | Altimmune Inc |
29/05/2024 | 13:31 | GlobeNewswire Inc. | Altimmune to Participate at Two Upcoming Investor Conferences | NASDAQ:ALT | Altimmune Inc |
29/05/2024 | 13:30 | GlobeNewswire Inc. | Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024 | NASDAQ:ALT | Altimmune Inc |
29/05/2024 | 11:45 | PR Newswire (US) | The Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline | NASDAQ:ALT | Altimmune Inc |
21/05/2024 | 15:00 | PR Newswire (US) | Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) | NASDAQ:ALT | Altimmune Inc |
21/05/2024 | 11:45 | PR Newswire (US) | The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT | NASDAQ:ALT | Altimmune Inc |
14/05/2024 | 11:45 | PR Newswire (US) | Contact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT) | NASDAQ:ALT | Altimmune Inc |